Thursday, January 17, 2013
Novartis AG researchers have
shown that the absence of pyruvate
kinase M2 isozyme has no effect on cancer cell proliferation
in mice and suggest that inhibiting the enzyme alone might not be an effective
strategy to stop tumor growth.1 The finding is surprising, given
that knocking down the target is known to impair proliferation of cultured
cancer cells. Biotechs working on modulators of the enzyme think it is too
early to write off the target.
PKM2 ups and
Biotechs contacted by SciBX said
it is too early to give up on targeting PKM2 because there is so much metabolic
variation from tumor to tumor.
Baas, T. SciBX 6(2); doi:10.1038/scibx.2013.28
Published online Jan 17, 2013
1. Cortés-Cros, M. et
al. Proc. Natl. Acad. Sci. USA; published online Dec. 24, 2012;
Contact: Marta Cortés-Cros, Novartis Institutes for BioMedical Research,
2. Christofk, H.R. et
al. Nature 452, 230-233 (2008)
3. Hitosugi, T. et al.
Sci. Signal. 2, ra73 (2009)
4. Anastasiou, D. et
al. Nat. Chem. Biol. 8, 839-847 (2012)
Agios Pharmaceuticals Inc., Cambridge, Mass.
Astex Pharmaceuticals Inc. (NASDAQ:ASTX), Dublin, Calif.
Dynamix Pharmaceuticals Ltd., Rehovot, Israel
Massachusetts Institute of Technology, Cambridge, Mass.
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
Tolero Pharmaceuticals Inc., Salt Lake City, Utah